-
Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey
Monday, February 27, 2017 - 9:17am | 400Read More...“While we see potential approval of two products this year and meaningful pipeline progress, we continue to believe BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is relatively expensive as it consistently trades at the top of peers,” Wedbush’s Liana Moussatos said in a note, while...
-
Baird Buying Ultragenyx And BioMarin
Tuesday, March 8, 2016 - 2:54pm | 542Read More...Baird has initiated coverage on Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) with an Outperform rating, citing diversified pipeline with multiple near-term catalysts. It also upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to Outperform with a $110 price target. Ultragenyx Ultragenyx's...
